To explore the acute and subchronic effects of GluN2A-containing NMDA receptor blockade on behavior, we targeted the dorsomedial prefrontal cortex (dmPFC), a region implicated in both depression [1] and schizophrenia [5, 6, 22, 58, 59]. This evidence concerns the gene GRIN2A and depressive symptom measurement.